WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced today that it will be exhibiting at the American Academy of Orthopedic Surgeons (AAOS) and presenting at the Orthopedic Research Society (ORS) Annual Meetings, which are held consecutively in New Orleans, LA, from March 6, 2018 to March 13, 2018.
During the AAOS Annual Meeting, from March 6, 2018 to March 10, 2018, attendees will be able to visit Histogenics at booth #5612 to learn more about NeoCart, Histogenics lead product candidate currently being studied in a Phase 3 randomized controlled clinical trial. NeoCart has been rigorously studied as a personalized restorative cell therapy for orthopedic use. NeoCart provides the only cartilage treatment that potentially rebuilds a patient’s own cartilage for rapid onset pain relief and restored function.
At the ORS Annual Meeting, on Saturday, March 10, 2018, Dr. Shuichi Mizuno, Ph.D., a scientific founder of NeoCart, Assistant Professor, Orthopedic Surgery, Brigham and Women’s Hospital, and Harvard Medical School, will deliver a podium presentation on NeoCart, entitled, “Platform Technologies for the Third Generation of Autologous Chondrocyte Implantation (NeoCart)”.
Additionally, three poster presentations on NeoCart will also be presented during the ORS Annual Meeting. These presentations will take place on Saturday, March 10, 2018 through Tuesday, March 13, 2018.
Title: Comparison of the Mechanical Properties of Tissue Engineered Cartilage Grown with Chondrocytes Differentiated from Human Induced Pluripotent Stem Cells versus Human Chondrocytes
Date and Time: Monday, March 12, 2018 and Tuesday, March 13, 2018
Title: Heterogeneous Matrix Deposition in Human Tissue Engineered Cartilage Decreases the Local Shear Mechanics
Date and Time: Saturday, March 10, 2018 and Sunday, March 11, 2018
Title: Hydrostatic Pressure Stimulates Production of Cell Adhesive Molecule by Synovial Cells
Date and Time: Monday, March 12, 2018 and Tuesday, March 13, 2018
The AAOS Annual Meeting brings orthopedic surgeons from around the world to share their research and experience at the Annual Meeting to deliver flagship education. To learn more about the AAOS Annual Meeting, visit www.aaos.org.
The ORS Annual Meeting is a leading forum for presentations of high quality, innovative and transformative research. For more information on the ORS Annual Meeting, visit www.ors.org.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Various statements in this release are “forward-looking statements” under the securities laws. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Important factors that could cause actual results to differ materially from those reflected in Histogenics’ forward-looking statements include, among others: the timing and success of Histogenics’ NeoCart Phase 3 clinical trial, including, without limitation, possible delays in generating the data from the clinical trial; the ability to obtain and maintain regulatory approval of NeoCart or any product candidates, the labeling for any approved products; NeoCart’s regulation as a Regenerative Medical Product; the market size and potential patient population in Japan; the scope, progress, expansion, and costs of developing and commercializing Histogenics’ product candidates; the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart raw materials following our technology transfer and manufacturing location transition; the size and growth of the potential markets for Histogenics’ product candidates and the ability to serve those markets; Histogenics’ expectations regarding its expenses and revenue; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Histogenics’ Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, which are on file with the SEC and available on the SEC’s website at www.sec.gov. Additional factors may be set forth in those sections of Histogenics’ Annual Report on Form 10-K for the year ended December 31, 2017, to be filed with the SEC in the first quarter of 2018. In addition to the risks described above and in Histogenics’ annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Histogenics’ results.
All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Tel: +1 (781) 547-7909